December 30, 2015

DSN examines chain pharmacy, including in-depth coverage of generics, specialty pharmacy and top trends, in this multi-page report.

December 9, 2015

DSN examines chain pharmacy, including in-depth coverage of generics, technology, automation, prescription drug home delivery services and Web-based diabetes monitoring, in this multi-page report.

November 11, 2015

DSN examines chain pharmacy, including in-depth coverage of generics, regulations, technology, automation and medication synchronization, in this multi-page report.

October 13, 2015

DSN examines chain pharmacy, including in-depth coverage of retail clinics, technology, automation, medication synchronization and generics, in this multi-page report.

September 23, 2015

The Wall Street Journal is examining the potential that biosimilars can have in the market for biotechnology drugs by looking at how they have been received in Europe to highlight their potential in the U.S. following the launch of Zarxio, the first U.S. biosimilar, earlier this month. 

September 16, 2015

Although growth has been high for new specialty and brand-name drugs in the past year, generics continue to be a central part of the U.S. pharmaceutical market.

September 11, 2015

DSN examines chain pharmacy, including in-depth coverage of retail clinics, technology, automation, medication synchronization and generics, in this multi-page report.

September 4, 2015

Pfizer said that the transaction has strengthened the company’s branded and generics portfolio, particularly when it comes to biosimilars.

September 3, 2015

 The drug, a biosimilar version of Amgen’s Neupogen, is the first biosimilar drug to launch in the U.S.

August 31, 2015

The guidance was outlined in a blog post by Janet Woodcock, director of the FDA’s center for drug evaluation and research, and Karen Midthum, director of the FDA’s center for biologics evaluation and research.

August 20, 2015

DSN examines chain pharmacy, including in-depth coverage of retail clinics, technology, automation, medication synchronization and generics, in this multi-page report.

July 27, 2015

The GpHA and Biosimilars Council have published their objections to the Trans-Pacific Partnership trade agreement to the pages of the New York Times. 

July 22, 2015

The Generic Pharmaceutical Association has appointed Chester “Chip” Davis, Jr. as president and CEO, replacing current CEO Ralph Neas effective Aug. 18.

July 22, 2015

Novartis will be able to introduce Sandoz’s Zarxio (filgrastim) after Sept. 2, the U.S. Court of Appeal for the Federal Circuit ruled Wednesday. 

July 15, 2015

DSN examines chain pharmacy, including in-depth coverage of technology, automation, medication synchronization and generics, in this multi-page report.

June 30, 2015

The GPhA's Biosimilars Council cautions FDA against adopting distinguishable names for biosimilars and biologics. 

June 15, 2015

DSN examines chain pharmacy, including in-depth coverage of technology, automation and generics, in this multi-page report.

May 26, 2015

Specialized manufacturers are gearing up for a robust trade out of generic biosimilar approvals, Kalorama reported last week. 

May 19, 2015

DSN examines chain pharmacy — including in-depth coverage of retail clinics, generics, consolidations, kiosks and more — in this multi-page report.

May 13, 2015

Five states now allow for automatic substitution for Food and Drug Administration approved interchangeable biologic products.

April 20, 2015

DSN examines chain pharmacy — including in-depth coverage of provider status, generics, pharmacy deserts, point-of-care testing and more — in this multi-page report.

April 17, 2015

Generic Pharmaceutical Association branches out with the creation of the Biosimilars Council. 

April 7, 2015

The Canadian Generic Pharmaceutical Association on Tuesday established a new Biosimilars Board. 

 

 

April 1, 2015

The cost of treating rheumatoid arthritis will reach $9.3 billion by 2020, according to a GBI Research report released Wednesday.